. .

 
Zuruecksetzen

Suchergebnis - GERON CORP. (DEL.) REGISTERED SHARES DL -,001

Zeit Titel
09.09 22:43dpa-AFX: *GERON CORP. APPOINTS JIM ZIEGLER AS CHIEF COMMERCIAL OFFICER
08.08 13:18dpa-AFX: Geron Corporation Q2 Loss Rises
08.08 13:12dpa-AFX: *GERON CORP. Q2 OPERATING LOSS $69.33 MLN VS. LOSS $51.95 MLN LAST YEAR
08.08 13:12dpa-AFX: *GERON CORP. Q2 NET LOSS $67.38 MLN VS. NET LOSS $49.23 MLN LAST YEAR
08.08 13:12dpa-AFX: *GERON CORP. Q2 REVENUES $882K VS. $29K LAST YEAR
08.08 13:06dpa-AFX: *GERON CORP. Q2 NET LOSS/SHR $0.10 VS. LOSS/SHR $0.09 LAST YEAR
08.08 13:01dpa-AFX: Geron Q2 24 Earnings Conference Call At 8:00 AM ET
26.07 13:35dpa-AFX: *GERON ANNOUNCES NCCN GUIDELINES UPDATE RECOMMENDING RYTELO FOR SYMPTOMATIC ANEMIA IN LOWER-RISK MDS
11.06 08:20dpa-AFX: *BARCLAYS STARTET GERON CORP MIT 'OVERWEIGHT' - ZIEL 9 USD
11.06 08:20dpa-AFX: *BARCLAYS STARTS GERON CORP WITH 'OVERWEIGHT' - PRICE TARGET 9 USD
07.06 17:40dpa-AFX: Geron Shares Rise After Rytelo Gets FDA Approval For Treatment Of Lower-risk MDS With TD Anemia
07.06 13:59dpa-AFX: *GERON VORBÖRSLICH +22% - FDA ERTEILT ZULASSUNG FÜR RYTELO GEGEN BLUTKRANKHEITEN
07.06 13:06dpa-AFX: Pre-market Movers: VERO, VS, BMEA, GME, VRAX.
07.06 04:18dpa-AFX: FDA Approves Geron's Rytelo For Treatment Of Lower-Risk MDS Anemia
02.05 13:23dpa-AFX: Geron Corporation Q1 Loss increases, but beats estimates
02.05 13:18dpa-AFX: *GERON Q1 REVENUES $304,000 VS $21,000 PRIOR YEAR
02.05 13:07dpa-AFX: *GERON Q1 NET LOSS WIDENS TO $55.4 MLN OR $0.09/SHR FROM $38.1 MLN OR $0.07/SHR PRIOR YEAR
10.04 15:16dpa-AFX: Geron To Present At Needham Virtual Healthcare Conference; Webcast At 10:15 AM ET
19.03 14:34dpa-AFX: Geron Announces Pricing Of $150 Mln Underwritten Offering Of Common Stock, Pre-Funded Warrants
19.03 14:10dpa-AFX: *GERON ANNOUNCES PRICING OF $150 MLN UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH